PF-05212377

DB16044InvestigationalSmall molecule

PF-05212377 is under investigation in clinical trial NCT01712074 (Study Evaluating Thesafety and Efficacy of PF-05212377 or Placebo in Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms on Donepezil).

Mechanism: Pharmacologically active on 5-hydroxytryptamine receptor 6
Curator reviewed
Formula / weight: C₁₈H₂₀N₄O₂S · 356.44 g/mol (avg)
Code names: PF-05212377 · PF-5212377 · SAM-760

Resolves to

Compound

UNII4JEH3BL51NCAS1226793-34-5ChEMBLCHEMBL3329435

Structure

InChIKeyMAYQIFVKVAUMPD-UHFFFAOYSA-NSMILESCC1=NC2=C(C=CC=C2N1S(=O)(=O)C1=CC=CC=C1)N1CCNCC1

Targets

P50406HTR6

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with PF-05212377, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account